Medical - Healthcare Information Services
Compare Stocks
2 / 10Stock Comparison
PGNY vs CI
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Healthcare Plans
PGNY vs CI — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Medical - Healthcare Information Services | Medical - Healthcare Plans |
| Market Cap | $1.57B | $74.85B |
| Revenue (TTM) | $1.29B | $277.94B |
| Net Income (TTM) | $68M | $6.29B |
| Gross Margin | 24.1% | 9.3% |
| Operating Margin | 7.5% | 3.4% |
| Forward P/E | 16.4x | 9.4x |
| Total Debt | $24M | $31.46B |
| Cash & Equiv. | $112M | $7.68B |
PGNY vs CI — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Progyny, Inc. (PGNY) | 100 | 76.8 | -23.2% |
| Cigna Corporation (CI) | 100 | 143.9 | +43.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: PGNY vs CI
Each card shows where this stock fits in a portfolio — not just who wins on paper.
PGNY is the clearest fit if your priority is sleep-well-at-night.
- Lower volatility, beta 0.71, Low D/E 4.7%, current ratio 2.73x
- 5.2% margin vs CI's 2.3%
- 9.0% ROA vs CI's 4.1%, ROIC 18.1% vs 10.4%
CI carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 6 yrs, beta 0.35, yield 2.1%
- Rev growth 11.3%, EPS growth 82.9%, 3Y rev CAGR 15.1%
- 136.5% 10Y total return vs PGNY's 20.2%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 11.3% revenue growth vs PGNY's 10.4% | |
| Value | Lower P/E (9.4x vs 16.4x) | |
| Quality / Margins | 5.2% margin vs CI's 2.3% | |
| Stability / Safety | Beta 0.35 vs PGNY's 0.71 | |
| Dividends | 2.1% yield; 6-year raise streak; the other pay no meaningful dividend | |
| Momentum (1Y) | -13.3% vs PGNY's -18.2% | |
| Efficiency (ROA) | 9.0% ROA vs CI's 4.1%, ROIC 18.1% vs 10.4% |
PGNY vs CI — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
PGNY vs CI — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
PGNY leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
CI is the larger business by revenue, generating $277.9B annually — 214.9x PGNY's $1.3B. Profitability is closely matched — net margins range from 5.2% (PGNY) to 2.3% (CI). On growth, CI holds the edge at +4.6% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $1.3B | $277.9B |
| EBITDAEarnings before interest/tax | $100M | $12.1B |
| Net IncomeAfter-tax profit | $68M | $6.3B |
| Free Cash FlowCash after capex | $181M | $7.7B |
| Gross MarginGross profit ÷ Revenue | +24.1% | +9.3% |
| Operating MarginEBIT ÷ Revenue | +7.5% | +3.4% |
| Net MarginNet income ÷ Revenue | +5.2% | +2.3% |
| FCF MarginFCF ÷ Revenue | +14.0% | +2.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | +1.4% | +4.6% |
| EPS Growth (YoY)Latest quarter vs prior year | +70.6% | +29.1% |
Valuation Metrics
CI leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
At 12.8x trailing earnings, CI trades at a 57% valuation discount to PGNY's 29.5x P/E. On an enterprise value basis, CI's 8.4x EV/EBITDA is more attractive than PGNY's 16.4x.
| Metric | ||
|---|---|---|
| Market CapShares × price | $1.6B | $74.9B |
| Enterprise ValueMkt cap + debt − cash | $1.5B | $98.6B |
| Trailing P/EPrice ÷ TTM EPS | 29.48x | 12.81x |
| Forward P/EPrice ÷ next-FY EPS est. | 16.39x | 9.36x |
| PEG RatioP/E ÷ EPS growth rate | 4.40x | — |
| EV / EBITDAEnterprise value multiple | 16.41x | 8.39x |
| Price / SalesMarket cap ÷ Revenue | 1.22x | 0.27x |
| Price / BookPrice ÷ Book value/share | 3.32x | 1.80x |
| Price / FCFMarket cap ÷ FCF | 8.18x | 8.92x |
Profitability & Efficiency
PGNY leads this category, winning 6 of 8 comparable metrics.
Profitability & Efficiency
CI delivers a 15.1% return on equity — every $100 of shareholder capital generates $15 in annual profit, vs $13 for PGNY. PGNY carries lower financial leverage with a 0.05x debt-to-equity ratio, signaling a more conservative balance sheet compared to CI's 0.75x. On the Piotroski fundamental quality scale (0–9), CI scores 8/9 vs PGNY's 6/9, reflecting strong financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | +13.3% | +15.1% |
| ROA (TTM)Return on assets | +9.0% | +4.1% |
| ROICReturn on invested capital | +18.1% | +10.4% |
| ROCEReturn on capital employed | +17.4% | +9.2% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 8 |
| Debt / EquityFinancial leverage | 0.05x | 0.75x |
| Net DebtTotal debt minus cash | -$88M | $23.8B |
| Cash & Equiv.Liquid assets | $112M | $7.7B |
| Total DebtShort + long-term debt | $24M | $31.5B |
| Interest CoverageEBIT ÷ Interest expense | — | 6.77x |
Total Returns (Dividends Reinvested)
CI leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CI five years ago would be worth $11,850 today (with dividends reinvested), compared to $3,705 for PGNY. Over the past 12 months, CI leads with a -13.3% total return vs PGNY's -18.2%. The 3-year compound annual growth rate (CAGR) favors CI at 4.4% vs PGNY's -18.1% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | -25.6% | +2.3% |
| 1-Year ReturnPast 12 months | -18.2% | -13.3% |
| 3-Year ReturnCumulative with dividends | -45.0% | +13.6% |
| 5-Year ReturnCumulative with dividends | -62.9% | +18.5% |
| 10-Year ReturnCumulative with dividends | +20.2% | +136.5% |
| CAGR (3Y)Annualised 3-year return | -18.1% | +4.4% |
Risk & Volatility
CI leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
CI is the less volatile stock with a 0.35 beta — it tends to amplify market swings less than PGNY's 0.71 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CI currently trades 83.8% from its 52-week high vs PGNY's 66.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.71x | 0.35x |
| 52-Week HighHighest price in past year | $28.75 | $338.89 |
| 52-Week LowLowest price in past year | $16.10 | $239.51 |
| % of 52W HighCurrent price vs 52-week peak | +66.6% | +83.8% |
| RSI (14)Momentum oscillator 0–100 | 57.6 | 53.5 |
| Avg Volume (50D)Average daily shares traded | 1.5M | 1.5M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates PGNY as "Buy" and CI as "Buy". Consensus price targets imply 60.8% upside for PGNY (target: $31) vs 15.5% for CI (target: $328). CI is the only dividend payer here at 2.13% yield — a key consideration for income-focused portfolios.
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $30.80 | $328.00 |
| # AnalystsCovering analysts | 20 | 39 |
| Dividend YieldAnnual dividend ÷ price | — | +2.1% |
| Dividend StreakConsecutive years of raises | — | 6 |
| Dividend / ShareAnnual DPS | — | $6.06 |
| Buyback YieldShare repurchases ÷ mkt cap | +5.2% | +4.8% |
CI leads in 3 of 6 categories (Valuation Metrics, Total Returns). PGNY leads in 2 (Income & Cash Flow, Profitability & Efficiency).
PGNY vs CI: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is PGNY or CI a better buy right now?
For growth investors, Cigna Corporation (CI) is the stronger pick with 11.
3% revenue growth year-over-year, versus 10. 4% for Progyny, Inc. (PGNY). Cigna Corporation (CI) offers the better valuation at 12. 8x trailing P/E (9. 4x forward), making it the more compelling value choice. Analysts rate Progyny, Inc. (PGNY) a "Buy" — based on 20 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — PGNY or CI?
On trailing P/E, Cigna Corporation (CI) is the cheapest at 12.
8x versus Progyny, Inc. at 29. 5x. On forward P/E, Cigna Corporation is actually cheaper at 9. 4x.
03Which is the better long-term investment — PGNY or CI?
Over the past 5 years, Cigna Corporation (CI) delivered a total return of +18.
5%, compared to -62. 9% for Progyny, Inc. (PGNY). Over 10 years, the gap is even starker: CI returned +136. 5% versus PGNY's +20. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — PGNY or CI?
By beta (market sensitivity over 5 years), Cigna Corporation (CI) is the lower-risk stock at 0.
35β versus Progyny, Inc. 's 0. 71β — meaning PGNY is approximately 100% more volatile than CI relative to the S&P 500. On balance sheet safety, Progyny, Inc. (PGNY) carries a lower debt/equity ratio of 5% versus 75% for Cigna Corporation — giving it more financial flexibility in a downturn.
05Which is growing faster — PGNY or CI?
By revenue growth (latest reported year), Cigna Corporation (CI) is pulling ahead at 11.
3% versus 10. 4% for Progyny, Inc. (PGNY). On earnings-per-share growth, the picture is similar: Cigna Corporation grew EPS 82. 9% year-over-year, compared to 14. 0% for Progyny, Inc.. Over a 3-year CAGR, PGNY leads at 17. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — PGNY or CI?
Progyny, Inc.
(PGNY) is the more profitable company, earning 4. 5% net margin versus 2. 2% for Cigna Corporation — meaning it keeps 4. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PGNY leads at 6. 6% versus 3. 3% for CI. At the gross margin level — before operating expenses — PGNY leads at 23. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is PGNY or CI more undervalued right now?
On forward earnings alone, Cigna Corporation (CI) trades at 9.
4x forward P/E versus 16. 4x for Progyny, Inc. — 7. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PGNY: 60. 8% to $30. 80.
08Which pays a better dividend — PGNY or CI?
In this comparison, CI (2.
1% yield) pays a dividend. PGNY does not pay a meaningful dividend and should not be held primarily for income.
09Is PGNY or CI better for a retirement portfolio?
For long-horizon retirement investors, Cigna Corporation (CI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
35), 2. 1% yield, +136. 5% 10Y return). Both have compounded well over 10 years (CI: +136. 5%, PGNY: +20. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between PGNY and CI?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: PGNY is a small-cap quality compounder stock; CI is a mid-cap deep-value stock. CI pays a dividend while PGNY does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.